ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 141 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2021. The put-call ratio across all filers is 1.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,120,179 | -29.6% | 4,204,264 | -0.1% | 0.07% | -20.5% |
| Q2 2023 | $5,849,487 | -12.6% | 4,208,264 | 0.0% | 0.08% | -14.4% |
| Q1 2023 | $6,691,140 | -75.2% | 4,208,264 | -2.8% | 0.10% | -72.9% |
| Q4 2022 | $26,977,545 | -4.7% | 4,330,264 | +2.5% | 0.36% | -11.8% |
| Q3 2022 | $28,309,000 | +5.1% | 4,225,264 | -0.2% | 0.41% | +6.6% |
| Q2 2022 | $26,936,000 | +35.0% | 4,235,264 | -1.5% | 0.38% | +64.2% |
| Q1 2022 | $19,948,000 | -11.7% | 4,299,164 | -4.9% | 0.23% | -0.4% |
| Q4 2021 | $22,596,000 | -58.5% | 4,519,164 | 0.0% | 0.23% | -57.9% |
| Q3 2021 | $54,455,000 | -43.0% | 4,519,164 | 0.0% | 0.55% | -40.7% |
| Q2 2021 | $95,580,000 | -14.6% | 4,519,164 | +13.3% | 0.93% | -21.2% |
| Q1 2021 | $111,896,000 | -16.2% | 3,989,164 | -22.4% | 1.18% | -22.6% |
| Q4 2020 | $133,599,000 | -34.2% | 5,138,451 | -6.0% | 1.53% | -45.5% |
| Q3 2020 | $203,160,000 | -25.3% | 5,465,715 | +3.1% | 2.81% | -27.1% |
| Q2 2020 | $272,104,000 | +71.3% | 5,303,135 | +5.3% | 3.85% | +25.0% |
| Q1 2020 | $158,844,000 | -41.1% | 5,037,890 | +11.3% | 3.08% | -28.0% |
| Q4 2019 | $269,826,000 | +73.5% | 4,525,010 | +6.7% | 4.28% | +47.9% |
| Q3 2019 | $155,492,000 | -17.6% | 4,241,461 | +4.5% | 2.89% | -10.3% |
| Q2 2019 | $188,750,000 | +848.7% | 4,057,411 | +718.8% | 3.22% | +194.3% |
| Q1 2019 | $19,896,000 | -4.3% | 495,547 | +9.6% | 1.10% | -19.9% |
| Q4 2018 | $20,791,000 | +19.6% | 451,972 | +15.3% | 1.37% | +23.9% |
| Q3 2018 | $17,386,000 | +41.5% | 391,852 | +25.0% | 1.10% | +5.3% |
| Q2 2018 | $12,287,000 | -1.6% | 313,520 | +81.5% | 1.05% | -15.4% |
| Q1 2018 | $12,493,000 | +2330.5% | 172,720 | +2114.4% | 1.24% | +2192.6% |
| Q4 2017 | $514,000 | +28.2% | 7,800 | -2.5% | 0.05% | +28.6% |
| Q3 2017 | $401,000 | +8.4% | 8,000 | 0.0% | 0.04% | -4.5% |
| Q2 2017 | $370,000 | -67.3% | 8,000 | -75.0% | 0.04% | -70.9% |
| Q1 2017 | $1,130,000 | +125.5% | 32,000 | -20.0% | 0.15% | +46.6% |
| Q4 2016 | $501,000 | -9.6% | 40,000 | 0.0% | 0.10% | +3.0% |
| Q3 2016 | $554,000 | +40.3% | 40,000 | 0.0% | 0.10% | +35.1% |
| Q2 2016 | $395,000 | -41.6% | 40,000 | 0.0% | 0.07% | -39.8% |
| Q1 2016 | $676,000 | – | 40,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |